Reducing peanut allergy risks in children -- The Nurse Practitioner presents update

February 15, 2018

Feb. 15, 2018 - New prevention and treatment approaches can reduce serious health risks due to peanut allergy in children, according to an article in the March issue of The Nurse Practitioner, published by Wolters Kluwer.

Early introduction of peanuts into the diet can prevent the development of peanut allergy in high-risk infants, according to the article by Jaime Hopper, MSN, FNP-C, and Courtney Hopp, MSN, FNP-C, of Indiana University Health Methodist Center, Indianapolis; and Jessica Durbin, DNP-FNP-BC, of Indiana State University, Terre Haute. The authors also discuss the emerging role of oral immunotherapy and other desensitization approaches to reduce serious reactions in peanut-allergic children.

What's New in Peanut Allergy? Update for Nurse Practitioners

With the rising prevalence of peanut and other food allergies, nurse practitioners and other providers must be prepared to care for children with peanut allergy. "Peanut allergies are a significant public health issue and are the primary reason for food-related anaphylactic reactions that result in death," the authors write. Rates of peanut allergy in the United States have been estimated between 1.6 and 2.7 percent.

Children who have siblings or parents with known peanut allergy are at increased risk of developing peanut allergy, as well as other food allergies, asthma, or atopic dermatitis. Until recently, the American Academy of Pediatrics (AAP) recommended avoiding peanuts in high-risk children until age three.

However, a 2015 study (the LEAP trial) found that early introduction of peanuts into the diet led to a "compelling reduction" in the risk of peanut allergy in high-risk children. The updated AAP recommendations define a three-tiered exposure level, including introducing peanuts at about four to six months of age in high-risk children with severe eczema and/or egg allergy, with a recommendation for allergy testing. Other recommendations apply to children with mild to moderate eczema, and to those with no eczema or any food allergy.

For children who have developed peanut allergy, a technique called oral immunotherapy (OIT) is a promising approach to allergen desensitization. In one trial, OIT increased the threshold amount of peanut children could ingest before experiencing a reaction by at least 25 times.

"With desensitization for known peanut allergies, clinicians may be able to reduce the incidence and other severe reactions in the future for children by making the reactions less severe," Hopper and coauthors write. "Although OIT has not been shown to be 100 percent effective, it offers the potential for an increased quality of life for severe food-allergy sufferers."

Further studies will be needed to establish the short- and long-term safety and effectiveness of OIT. Sublingual and epicutaneous approaches to peanut immunotherapy are being studied as well.

The authors discuss the implications for evaluation and management of children receiving immunotherapy for peanut allergy, including assessment of asthma and other forms of allergic disease. Patients need ongoing education in recognition and emergency treatment of life-threatening allergic reactions, including the use of an epinephrine auto-injector.

The theory that early introduction of highly allergic foods could desensitize patients and lead to fewer adverse reactions could lead to major changes in the management of food allergies. "While currently utilized by clinicians in specialty settings and still experimental in nature, the potential exists for administration of OIT into other clinical sites," the article notes. "This would further advance the availability of lifesaving therapies to the most vulnerable individuals in our population."
-end-
Click here to read "Peanut allergy reduction in high-risk pediatric patients."

DOI: 10.1097/01.NPR.0000530210.24654.36

About The Nurse Practitioner

With a circulation of 75,000, The Nurse Practitioner is the leading monthly source for clinical, practical, cutting-edge information for advanced practice nurses and other primary care clinicians. Each issue presents peer-reviewed articles that range from clinical topics and research to political and practice issues. In addition, The Nurse Practitioner provides regular features, columns, continuing education, staff development education, and more. In addition, The Nurse Practitioner holds a biannual educational meeting--the National Conference for Nurse Practitioners (NCNP) -- which draws approximately 3,000 attendees annually.

About Wolters Kluwer

Wolters Kluwer N.V. (AEX: WKL) is a global leader in information services and solutions for professionals in the health, tax and accounting, risk and compliance, finance and legal sectors. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with specialized technology and services.

Wolters Kluwer reported 2016 annual revenues of €4.3 billion. The company, headquartered in Alphen aan den Rijn, the Netherlands, serves customers in over 180 countries, maintains operations in over 40 countries and employs 19,000 people worldwide.

Wolters Kluwer Health is a leading global provider of information and point of care solutions for the healthcare industry. For more information about our products and the organization, visit http://www.wolterskluwer.com/, follow @WKHealth or @Wolters_Kluwer on Twitter, like us on Facebook, follow us on LinkedIn, or follow WoltersKluwerComms on YouTube.

For more information about Wolters Kluwer's solutions and organization, visit http://www.wolterskluwer.com, follow us on Twitter, Facebook, LinkedIn, and YouTube.

Wolters Kluwer Health

Related Eczema Articles from Brightsurf:

Vitamin D lessens symptoms of severe eczema in children
Vitamin D supplementation eased the symptoms experienced by children with severe atopic dermatitis, or eczema, in a recent randomized controlled trial published in Pharmacology Research & Perspectives.

TV ads for psoriasis and eczema medications portray few people of color
Commercials from pharmaceutical companies advertising medication to treat psoriasis and eczema lack people from racial and ethnic minorities, according to research from the Perelman School of Medicine at the University of Pennsylvania.

NIH-supported scientists demonstrate how genetic variations cause eczema
New research supported by the National Institutes of Health delineates how two relatively common variations in a gene called KIF3A are responsible for an impaired skin barrier that allows increased water loss from the skin, promoting the development of atopic dermatitis, commonly known as eczema.

Biomedical researchers get closer to why eczema happens
A new study from researchers at Binghamton University, State University of New York may help to peel back the layers of unhealthy skin -- at least metaphorically speaking -- and get closer to a cure.

Researchers uncover novel approach for treating eczema
Researchers at the University of British Columbia (UBC) and Vancouver Coastal Health Research Institute (VCHRI) have identified a key enzyme that contributes to eczema, which may lead to better treatment to prevent the skin disorder's debilitating effects.

Revving up immune system may help treat eczema
Studying eczema, researchers at Washington University School of Medicine in St.

Childhood eczema cannot be prevented by daily moisturiser use, study finds
Using moisturisers on newborn babies does not prevent eczema as previously thought, according to a major new study.

Atopic eczema linked to increase fracture risk in adults
Adults with atopic eczema could face a raised risk of fracture, with the risk increasing the more severe the condition, according to a new study published in the Journal of Allergy and Clinical Immunology.

Long-term dupilumab benefits adolescents with eczema
Results from a phase IIa open-label trial and a subsequent phase III open-label extension trial reinforce findings from an earlier short-term trial that adolescents with moderate-to-severe atopic dermatitis, or eczema, can experience significant improvements with dupilumab.

Multiple genes affect risk of asthma, hay fever and eczema
In a new study from SciLifeLab at Uppsala University, researchers have found a total of 141 regions (genes) in our genetic material that largely explain the genetic risk underlying asthma, hay fever and eczema.

Read More: Eczema News and Eczema Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.